Exome Asset Management
Latest statistics and disclosures from Exome Asset Management's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0002011932
Tip: Access up to 7 years of quarterly data
Positions held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Exome Asset Management
Exome Asset Management holds 52 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Dr Reddys Labs Adr (RDY) | 6.2 | $6.3M | 90k | 69.58 |
|
|
| Eli Lilly & Co. (LLY) | 5.6 | $5.7M | 9.7k | 582.92 |
|
|
| ImmunoGen | 5.5 | $5.5M | 187k | 29.65 |
|
|
| Cigna Corp (CI) | 4.5 | $4.6M | 15k | 299.45 |
|
|
| Celldex Therapeutics Com New (CLDX) | 4.4 | $4.4M | 111k | 39.66 |
|
|
| Tg Therapeutics (TGTX) | 3.4 | $3.5M | 203k | 17.08 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 3.3 | $3.3M | 72k | 45.97 |
|
|
| Alpine Immune Sciences (ALPN) | 3.3 | $3.3M | 174k | 19.06 |
|
|
| Dex (DXCM) | 3.0 | $3.1M | 25k | 124.09 |
|
|
| Madrigal Pharmaceuticals (MDGL) | 3.0 | $3.1M | 13k | 231.38 |
|
|
| Cytokinetics Com New (CYTK) | 2.9 | $2.9M | 35k | 83.49 |
|
|
| Inhibrx (INBX) | 2.7 | $2.8M | 73k | 38.00 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.7 | $2.8M | 68k | 40.76 |
|
|
| Rocket Pharmaceuticals (RCKT) | 2.7 | $2.8M | 92k | 29.97 |
|
|
| Bridgebio Pharma (BBIO) | 2.6 | $2.6M | 65k | 40.37 |
|
|
| Beigene Sponsored Adr (BGNE) | 2.3 | $2.3M | 13k | 180.36 |
|
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 2.3 | $2.3M | 38k | 60.17 |
|
|
| Penumbra (PEN) | 2.1 | $2.2M | 8.6k | 251.54 |
|
|
| Intuitive Surgical Com New (ISRG) | 2.1 | $2.1M | 6.4k | 337.36 |
|
|
| Biogen Idec (BIIB) | 2.1 | $2.1M | 8.2k | 258.77 |
|
|
| Intra Cellular Therapies (ITCI) | 2.0 | $2.0M | 28k | 71.62 |
|
|
| Biohaven (BHVN) | 1.9 | $1.9M | 46k | 42.80 |
|
|
| Insmed Com Par $.01 (INSM) | 1.9 | $1.9M | 62k | 30.99 |
|
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 1.8 | $1.8M | 29k | 62.00 |
|
|
| Catalyst Pharmaceutical Partners (CPRX) | 1.8 | $1.8M | 106k | 16.81 |
|
|
| Tarsus Pharmaceuticals (TARS) | 1.7 | $1.7M | 84k | 20.25 |
|
|
| Shattuck Labs (STTK) | 1.6 | $1.6M | 223k | 7.13 |
|
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.6 | $1.6M | 3.9k | 406.89 |
|
|
| Immatics SHS (IMTX) | 1.4 | $1.4M | 130k | 10.53 |
|
|
| Prothena Corp SHS (PRTA) | 1.3 | $1.3M | 36k | 36.34 |
|
|
| Geron Corporation (GERN) | 1.3 | $1.3M | 608k | 2.11 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.2 | $1.2M | 693k | 1.77 |
|
|
| Macrogenics (MGNX) | 1.2 | $1.2M | 126k | 9.62 |
|
|
| Natera (NTRA) | 1.2 | $1.2M | 19k | 62.64 |
|
|
| Igm Biosciences (IGMS) | 1.1 | $1.1M | 136k | 8.31 |
|
|
| Cabaletta Bio (CABA) | 1.0 | $1.1M | 47k | 22.70 |
|
|
| Mirati Therapeutics | 0.9 | $934k | 16k | 58.75 |
|
|
| Pliant Therapeutics (PLRX) | 0.9 | $898k | 50k | 18.11 |
|
|
| Sage Therapeutics (SAGE) | 0.8 | $764k | 35k | 21.67 |
|
|
| Shockwave Med (SWAV) | 0.8 | $762k | 4.0k | 190.56 |
|
|
| Travere Therapeutics (TVTX) | 0.7 | $755k | 84k | 8.99 |
|
|
| Pacific Biosciences of California (PACB) | 0.7 | $739k | 75k | 9.81 |
|
|
| Establishment Labs Holdings Ord (ESTA) | 0.7 | $715k | 28k | 25.89 |
|
|
| Sutro Biopharma (STRO) | 0.7 | $659k | 154k | 4.29 |
|
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.6 | $610k | 26k | 23.11 |
|
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.6 | $588k | 9.7k | 60.39 |
|
|
| Procaps Group Sa SHS (PROC) | 0.5 | $517k | 127k | 4.07 |
|
|
| Apellis Pharmaceuticals (APLS) | 0.4 | $434k | 7.2k | 59.86 |
|
|
| Gracell Biotechnologies Sponsored Ads | 0.4 | $411k | 41k | 10.04 |
|
|
| Vyne Therapeutics (VYNE) | 0.3 | $275k | 118k | 2.33 |
|
|
| Regulus Therapeutics (RGLS) | 0.2 | $228k | 178k | 1.28 |
|
|
| Kinnate Biopharma (KNTE) | 0.2 | $199k | 84k | 2.37 |
|
Past Filings by Exome Asset Management
SEC 13F filings are viewable for Exome Asset Management going back to 2023
- Exome Asset Management 2023 Q4 filed Feb. 15, 2024